Turn Therapeutics Drops Updated Investor Deck with Strong Interim Phase 2 Data and Cash Runway into Q3 2027
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics' new investor presentation reveals strong interim Phase 2 data for GX-03 in atopic dermatitis, with a 61.5% vIGA-AD success rate vs 8.3% for vehicle, and confirms cash runway into Q3 2027.
Key Events · Product Development and Regulatory · TTRX
-
Interim Phase 2 Data Released
Representative subgroup (n=25) showed 61.5% vIGA-AD success for GX-03 vs 8.3% for vehicle (p=0.01), with EASI-75 at 69.2% vs 25.0% (p=0.04).
-
Cash Runway Extended
$11.2M cash as of March 31, 2026, funds operations into Q3 2027; ~29.8M shares outstanding.
-
Upcoming Milestones
Q4 2026 topline AD readout, Q1 2027 onychomycosis Phase 3 start, Q2 2027 HS Phase 2a start, and Q4 2026 FDA Type B meeting.
-
Stage 2 Design Optimized
Adaptive design enriched for PP-NRS ≥7, powered to >99.8% across four endpoints using Hochberg method.
Analysis · TTRX · Life Sciences
Turn Therapeutics released an updated investor presentation containing new, detailed interim Phase 2 data for its lead atopic dermatitis candidate GX-03. The representative subgroup showed a 61.5% vIGA-AD success rate versus 8.3% for vehicle (p=0.01), with treatment separation across all four selected endpoints. The company also disclosed a cash balance of $11.2 million as of March 31, 2026, providing runway into Q3 2027, and outlined upcoming milestones including a Q4 2026 topline readout. This is the first time the market sees the optimized Stage 2 design and the specific financial runway extension, making it a material update on both clinical progress and funding status.
At the time of this filing, TTRX was trading at $8.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231.8M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.